Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 12, 2025Leukemia & lymphoma/Leukemia and lymphoma

Clinical outcomes of allogeneic cell transplantation for patients with chronic myeloid leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

BMBenjamin J. McCormickAFAngelica FindleyKDKendall Diebold

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows overall survival rates in leukemia types after transplantation, indicating disease biology influences outcomes.

Key Points

  • Median overall survival was 50 months in myeloid blast phase, indicating varied outcomes based on leukemia type.
  • Patients in transformed myeloid blast phase had worse relapse rates compared to those in lymphoid blast phase.
  • Allo-HCT demonstrated efficacy in treating TKI-resistant chronic myeloid leukemia with varied survival based on cytogenetic features.
  • Post-transplant maintenance with TKI did not significantly improve relapse or survival rates in this cohort.

Cite This Study

McCormick et al. (2025) studied this question.

synapsesocial.com/papers/68eb8fe250220ac955d94c2ehttps://doi.org/10.1080/10428194.2025.2564766
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Long-term outcomes of CML patients undergoing hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors2025
  2. 2Clinical characteristics and prognostic factors in myeloid blast-Phase chronic myeloid leukemia2025
  3. 3Enhanced outcomes for pediatric patients with de novo chronic myeloid leukemia in blast Phase through early allogeneic stem cell transplantation and tyrosine kinase inhibitor2025
  4. 4Survival impact of post-transplant tyrosine kinase inhibitor therapy in chronic myeloid leukemia.2026
  5. 5Outcomes of pediatric patients transplanted for B-ALL with high-risk cytogenetics- a 20-year experience from LMIC setting2025